Loading
Non Small Lung Cancer / Sotorasib · Phase 2 Trial
ClinicalTrials.gov · September 11, 2026
Early or partial results. Treat as a signal, not a conclusion.
This is a Phase 2 trial registration for sotorasib in treatment-naive advanced NSCLC harboring KRAS G12C mutation, currently recruiting. No results are posted in this registry record; the study is in progress and has not yet reported efficacy or safety outcomes.
Phase 2, Interventional, Single Group, Open label, Treatment purpose. Non Small Lung Cancer; age from 18 Years. Intervention: Sotorasib. n = 39. 7 sites: United States.
This is a Phase 2 trial registration for sotorasib in treatment-naive advanced NSCLC harboring KRAS G12C mutation, currently recruiting. No results are posted in this registry record; the study is in progress and has not yet reported efficacy or safety outcomes.
No efficacy, safety, or response data are available.
This trial is exploratory and will inform whether sotorasib merits further investigation in the first-line treatment-naive KRAS G12C NSCLC population. No clinical recommendations should be drawn from this registry record alone.
This is a Phase 2 clinical trial registration with no posted results; it describes a planned study of sotorasib in treatment-naive advanced NSCLC with KRAS G12C mutation, currently recruiting.
As stated by the source record.
Quoted from the source exactly as published.
This trial is exploratory and will inform whether sotorasib merits further investigation in the first-line treatment-naive KRAS G12C NSCLC population. No clinical recommendations should be drawn from this registry record alone.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT06582771). This is a study registration, not published results. Lead sponsor: Memorial Sloan Kettering Cancer Center. Recruitment status: RECRUITING. Phase: PHASE2. Study type: INTERVENTIONAL. Enrollment: 39 participants (ESTIMATED). Conditions: Non Small Lung Cancer. Interventions: DRUG: Sotorasib. Primary outcome measures: Response to therapy , within 6 month of therapy. Brief summary: The researchers are doing this study to see if sotorasib is a safe and effective treatment for people with advanced non-small cell lung cancer (NSCLC) with a KRAS G12C mutation who have not received treatment for their cancer since it became advanced. (Participants have not received a "first-line therapy" since their cancer became advanced.)
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.